Unibest

Pharmaceutical intermediates

Linperlisib Intermediates

1 pharmaceutical intermediate for Linperlisib. Indication: Follicular lymphoma.

Submit a ProjectAll intermediates

About Linperlisib

Originator
Shanghai Haoyuan Pharmaceutical Co., Ltd
Indication
Follicular lymphoma
Approved Date
11/08/2022

Available intermediates

1 intermediate currently listed for Linperlisib. Request specifications, documentation or a quotation for any item below.

Linperlisib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-pyridin-3-ylamine893440-50-1//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Linperlisib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →